<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: In the era of DNA-guided personalized <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment, it is essential to conduct predictive analysis on the tissue that matters </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we analyzed genetic differences between primary colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and their respective <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: The primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and the subsequent <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> of 21 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were analyzed using targeted deep-sequencing of DNA isolated from formalin-fixed, paraffin-embedded archived material </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We have interrogated the genetic constitution of a designed "<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Mini-Genome" consisting of <z:hpo ids='HP_0000001'>all</z:hpo> exons of 1,264 genes associated with pathways relevant to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In total, 6,696 known and 1,305 novel variations were identified in 1,174 and 667 genes, respectively, including 817 variants that potentially altered protein function </plain></SENT>
<SENT sid="5" pm="."><plain>On average, 83 (SD = 69) potentially function-impairing variations were gained in the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and 70 (SD = 48) variations were lost, showing that the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> are genetically significantly different </plain></SENT>
<SENT sid="6" pm="."><plain>Besides novel and known variations in genes such as KRAS, BRAF, KDR, FLT1, PTEN, and PI3KCA, aberrations in the up/downstream genes of EGFR/PI3K/VEGF-pathways and other pathways (mTOR, TGFÎ², etc.) were also detected, potentially influencing therapeutic responsiveness </plain></SENT>
<SENT sid="7" pm="."><plain>Chemotherapy between removal of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (N = 11) did not further increase the amount of genetic variation </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Our study indicates that the genetic characteristics of the <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> are different from those of the primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>As a consequence, the choice of treatment in studies investigating targeted therapies should ideally be based on the genetic properties of the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> rather than on those of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
</text></document>